This European drug maker has hit an apparent home run with their Ozempic drug.  As a diabetes drug, it is currently being prescribed off-label for weight loss.  That is expected to change once the FDA has approved it to treat obesity.  With an estimated 60+% of the US population categorized as obese or overweight, the addressable market for drugs that are effective and safe is massive.  The company also sports strong profit and operating margins.